Vincristine Sulfate

CHEMBL501867 Phase 4 معتمد Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

923.0 g/mol

LogP

—

Phase

4

A sulfate salt form of vincristine with the same therapeutic properties. This plant-derived chemotherapy medication disrupts the formation of the mitotic spindle that cancer cells need to divide, and is a mainstay of treatment for leukemia, lymphoma, and certain pediatric solid tumors.

الوزن الجزيئي

923,0000 g/mol

TPSA

254,00 Å²

المجالات العلاجية

Melanoma Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Non-Small Cell Lung Cancer Gastroesophageal Reflux Disease Inflammatory Bowel Disease Non-Alcoholic Fatty Liver Disease Oncology Lymphoma Breast Cancer HIV/AIDS Prostate Cancer Colorectal Cancer Leukemia

Pharmacokinetics (PK)

Pharmacodynamics (PD)

البنية ثنائية الأبعاد

SVG PNG

Cite this structure

Embed this structure

SMILES

CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O

InChI

InChI=1S/C46H56N4O10.H2O4S/c1-7-42(55)22-28-23-45(40(53)58-5,36-30(14-18-48(24-28)25-42)29-12-9-10-13-33(29)47-36)32-20-31-34(21-35(32)57-4)50(26-51)38-44(31)16-19-49-17-11-15-43(8-2,37(44)49)39(60-27(3)52)46(38,56)41(54)59-6;1-5(2,3)4/h9-13,15,20-21,26,28,37-39,47,55-56H,7-8,14,16-19,22-25H2,1-6H3;(H2,1,2,3,4)/t28-,37+,38-,39-,42+,43-,44-,45+,46+;/m1./s1

Molecular Formula

C46H58N4O14S

HBD / HBA

5 / 16

الروابط القابلة للدوران

10

الذرات الثقيلة

65

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

الأسئلة الشائعة

A sulfate salt form of vincristine with the same therapeutic properties. This plant-derived chemotherapy medication disrupts the formation of the mitotic spindle that cancer cells need to divide, and is a mainstay of treatment for leukemia, lymphoma, and certain pediatric solid tumors.

Yes, Vincristine Sulfate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL501867. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 249332. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

هل تبحث عن معلومات ملائمة للمرضى؟

Vincristine Sulfate على PillFYI

البنية

بيانات سريعة

الصيغة الجزيئية: C46H58N4O14S

روابط خارجية

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

إخلاء المسؤولية الطبية

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.